Work

Beyond Gene Therapy: Experimental Perspectives of Gene Therapy in Hemoglobinopathies

Year: 2025

Type: article

Abstract: β-hemoglobinopathies are caused by mutations affecting adult hemoglobin β-chain production. The only curative treatment is allogenic hematopoietic stem/progenitor cells (HSPCs) transplantation, an approach limited by compatible donor availability and immunological complications. Therefore, transplantation of autologous, genetically modified HSPCs is an attractive therapeutic option. However, current gene therapy strategies based on the use of lentiviral vectors or CRISPR/Cas9 nuclease are not equally effective in all the patients and/or raise safety concerns. Base, prime and epigenome editing are novel, promising CRISPR/Cas9-based genome editing technologies that allow the introduction of mutations in the DNA generating few or no dangerous double strand breaks. We will discuss the different genome editing strategies aiming either to correct the genetic defect or target disease modifiers in patient cells and provide a safe and effective treatment for β-hemoglobinopathies.

Source: DOAJ (DOAJ: Directory of Open Access Journals)

Author: A. Miccio

Institutions: Inserm, Université Paris Cité, Institut des Maladies Génétiques Imagine

Language: English

Topic: Virus-based gene therapy research

Subfield: Genetics

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W7093122303

FWCI:

Cites:

Cited by:

Related to: